Left Ventricular Dysfunction denials in California external review
In the California DMHC record, independent physician reviewers decided 12 published external-review cases involving left ventricular dysfunctionand overturned the plan’s denial in 58.3%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
Most-fought treatments for left ventricular dysfunction
| Category | Decisions | Overturned |
|---|---|---|
| Wearable Cardioverter Defibrillator | 5 | 40% |
| Zoll Life Vest | 3 | 66.7% |
What the insurer actually argued
| Reason given | Decisions | Overturned |
|---|---|---|
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 9 | 55.6% |
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 3 | 66.7% |
What the reviewers wrote
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: enrollee has requested reimbursement for the wearable cardioverter defibrillator (WCD) for evaluation of the enrollee’s diabetes, hypertension, and non ST elevation myocardial infarction (STEMI). Findings: The physician reviewer found that current data from multiple trials and registries have advocated the use of a WCD after an initial diagnosis of severe left ventricular dysfunction as demonstrated by an ejection fraction less than 35%. This patient’s ejection fraction was estimated at 15%. The American College of Cardiology (ACC) and American Heart Association (AHA) recommend against placing an implantable cardioverter defibrillator within three months of the initial diagnosis of heart failure, within 40 days of myocardial infarction, or within three months of coronary revascularization.
Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for the Zoll LifeVest (HCPCS K0606). The documented high risk of sudden cardiac death in patients with severe left ventricular dysfunction has led to the recommendation of implantable cardioverter defibrillators in this group of patients. Current data from multiple trials have advocated the use of a wearable cardioverter defibrillator after an initial diagnosis of severe left ventricular dysfunction with a left ventricle ejection fraction (LVEF) less than or equal to 35%. This patient’s LVEF was 30-35%.
Where the denial was upheld
Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for a LifeVest. In this circumstance, there is potential for recovery of left ventricular function over time with medical therapy, and there was no documented indication for immediate placement of a defibrillator such as sustained or inducible ventricular tachycardia, unexplained syncope or aborted sudden cardiac arrest. Placement of a prophylactic defibrillator is not recommended until at least 90 days have elapsed with continued left ventricular dysfunction demonstrated by an ejection fraction less than 35% despite appropriate treatment. A prophylactic defibrillator before this time has not been demonstrated to improve outcome.
Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for the Life Vest wearable cardioverter defibrillator (WCD) for treatment of the enrollee’s ST elevation myocardial infarction (STEMI) involving left anterior descending (LAD) coronary artery, atrial flutter, and acute respiratory failure. Findings: Two physician reviewers found that based on the records provided, the patient presented with severe left ventricular dysfunction soon after coronary stenting for acute myocardial infarction. Cardiac arrest in the immediate acute infarction period generally does not increase risk of subsequent cardiac arrest.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving left ventricular dysfunction, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY